Trial Information

Summary: Hemophilic Genotype, Inhibitors and Response to Immune Tolerance

You and your child have been asked to participate in this research study because your child is known to have Hemophilia A, an inherited bleeding disorder. Bleeding in persons with hemophilia A occurs because a clotting protein, called factor VIII (FVIII), either is missing or doesn't work as it is supposed to. Your child has been treated with FVIII replacements in the past in order to control or prevent bleeding events, and your child has had an immune reaction to the FVIII, called and inhibitor. People who have an inhibitor do not respond to treatment with factor replacement, and your child is in a study called the Immune Tolerance Induction (ITI) study because he has this problem. This study is a companion study to the ITI Study. The purpose of this study is to find out if changes in the FVIII gene that causes hemophilia may predict response to FVIII replacement and to Immune Tolerance Induction. Your child's participation in this companion study is expected to last approximately six months, from the time his sample is sent to the Genotyping lab until the lab reports its finding to the study office.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: August 4, 2008 at 1:56:46 PM